“NLX-101 for the Treatment of Rett Syndrome”

In Clinical Development, Featured on App, Orphan Drug Congress by Freya SmaleLeave a Comment

MarkVarneyPresImage
Mark Varney of Neurolixis  joined us at World Orphan Drug Congress USA 2015 to present about ‘ NLX-101 for the Treatment of Rett Syndrome’. 

Download the presentation now to learn about:

  • Rett Syndrome: Key Facts
  • Pleiotropy in Rett Syndrome
  • NLX-101: A selective 5-HT 1A  receptor “biased agonist” 
…and much more!
Get your copy here!
To find out more about  NLX-101 as a treatment of Rett Syndrome , join us at World Orphan Drug Congress USA 2016 April 20-22 in Washington, DC.

Leave a Comment